WINDLAS vs WOCKPHARMA: Stock Comparison

Windlas Biotech Ltd vs Wockhardt Ltd

Live data: 22 July 2026, 3:00 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Windlas Biotech Ltd shows a lower P/E, a higher ROE and a higher dividend yield, while Wockhardt Ltd shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Windlas Biotech Ltd and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, WINDLAS is more favourable on 8 of 13 scored metrics and WOCKPHARMA on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹1,804 Cr
P/E Ratio
WINDLAS has a lower P/E
28x vs 144.46x
P/B Ratio
WINDLAS has a lower P/B
3.2x vs 6.23x
EPS
WINDLAS has higher earnings per share
₹31.5 vs ₹13.1
Dividend Yield
WINDLAS has a higher dividend yield
0.72% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 17.7%
EPS Growth (TTM YoY)
WOCKPHARMA has faster EPS growth
0% vs -2.6%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs 17.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricWINDLASWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricWINDLASWOCKPHARMA
Live Price₹870₹1,867
Day Change-1.19%-1.55%
Volume33,2217.17 L
52-Week High₹1,097.9₹2,422.3
52-Week Low₹697.4₹1,086.7
Distance from 52W High-20.76%-22.92%

Valuation

MetricWINDLASWOCKPHARMA
Market Cap₹1,804 Cr₹30,362 Cr
P/E Ratio28x144.46x
P/B Ratio3.2x6.23x
EPS₹31.5₹13.1
Book Value₹275₹304
Dividend Yield0.72%0%

Growth

MetricWINDLASWOCKPHARMA
Revenue Growth (TTM YoY)17.7%26%
EPS Growth (TTM YoY)-2.6%0%
Qtr Sales Growth17.7%29.9%
Qtr Profit Growth-1.78%688%

Profitability & Leverage

MetricWINDLASWOCKPHARMA
ROE12.2%6.11%
ROCE15.9%7.55%
Net Margin7.35%3.3%
Operating Margin11.6%19.3%
Debt to Equity0.06x0.45x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricWINDLASWOCKPHARMA
Promoter Holding63.31% 1.41 pp49.08%
FII Holding2.04% 1.44 pp7.09% 0.1 pp
DII Holding9.84% 1.97 pp10.96% 0.41 pp
Public Holding24.8% 0.9 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Windlas Biotech Ltd and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.